Abstract
Pancreatic adenocarcinoma patients have poor survival outcomes and there are no non-invasive tests to aid diagnosis or therapy. Detection of circulating tumour DNA (ctDNA) methylated for BCAT1 and/or IKZF1 is over 60% sensitive for colorectal adenocarcinoma. Both pancreatic and colorectal adenocarcinomas are of endodermal origin, therefore, these methylated biomarkers might also have utility in detecting pancreatic cancer. The aim of this study was to investigate whether individuals with pancreatic adenocarcinoma have detectable methylated BCAT1 and IKZF1 DNA in circulation.
Original language | English |
---|---|
Number of pages | 2 |
Journal | Journal of Clinical Oncology |
Volume | 40 |
Issue number | 4 suppl |
DOIs | |
Publication status | Published - 1 Feb 2022 |
Event | 2022 ASCO Gastrointestinal Cancers Symposium - San Francisco, United States Duration: 20 Jan 2022 → 22 Jan 2022 |
Keywords
- BCAT1
- IKZF1
- pancreatic adenocarcinoma
- circulating tumor DNA
- biomarkers
- ctDNA
- pancreatic cancer